Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HUA MEDICINE

6 ï < ¹

(Incorporated in the Cayman Islands with limited liability)

(stock code: 2552)

PROFIT WARNING

This announcement is made by Hua Medicine (the "Company" together with its subsidiaries the "Group") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "Board") of directors (the "Directors") of the Company wishes to inform the shareholders of the Company (the "Shareholders") and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group for the six months ended June 30, 2026 (the "Current Reporting Period") and information currently available to the Group, the Group expects to record a loss of approximately RMB30.2 million for the Current Reporting Period as compared with a profit for the period of approximately RMB1,183.9 million for the corresponding period in 2025.

The change in results is mainly attributable to the absence of the one-off release of contract liabilities to other income of approximately RMB1,243.5 million in the corresponding period of 2025 following the termination of the Bayer contract. Excluding the effect of this non-recurring item, the Group's loss for the Current Reporting Period is expected to narrow by approximately RMB29.4 million as compared with the adjusted loss of approximately RMB59.6 million for the corresponding period in 2025. The narrowing of the Group's loss on an adjusted basis is mainly attributable to the increase in revenue and improved gross profit margin.

The Company is still in the process of finalising the results of the Group for the Current Reporting Period and the information contained in this announcement represents preliminary statistics and a preliminary assessment based on the management accounts of the Group which has not been audited or reviewed by the Company's auditor. Shareholders and potential investors are advised to refer to the interim results announcement of the Company for the Current Reporting Period to be published in August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Dr. Li Chen
Chief Executive Officer and Executive Director

Hong Kong, August 7, 2026

As of the date of this announcement, the Board of Directors comprises Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang as executive Directors; Mr. Robert Taylor Nelsen as non-executive Director; and Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung as independent non-executive Directors.